The relatively low and variable display of CD33 on AML cells—there are on average ~104 CD33 molecules per AML blast, and antigen density varies greater than 2-log-fold across individual patients—may be one reason to account for this difficulty. Here, CD33 is linked to acute myeloid leukemia.